Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development-Reference-Cited by-同舟云学术

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development

Published:2020-11-21 Issue:1 Volume:110 Page:64-68
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Boffito Marta¹²,Back David J.³,Flexner Charles⁴,Sjö Peter⁵,Blaschke Terrence F.⁶,Horby Peter W.⁷,Cattaneo Dario⁸,Acosta Edward P.⁹,Anderson Peter¹⁰,Owen Andrew³¹¹

Affiliation:

1. Chelsea & Westminster Hospital London UK

2. Department of Infectious Disease Imperial College London London UK

3. Department of Pharmacology and Therapeutics University of Liverpool Liverpool UK

4. Bloomberg School of Public Health Johns Hopkins University School of Medicine Baltimore Maryland USA

5. Drugs for Neglected Diseases Initiative (DNDi) Geneva Switzerland

6. Department of Medicine Stanford University School of Medicine Stanford California USA

7. Centre for Tropical Medicine and Global Health Nuffield Department of Medicine University of Oxford Oxford UK

8. Unit of Clinical Pharmacology ASST Fatebenefratelli Sacco University Hospital Milan Italy

9. Department of Pharmacology and Toxicology University of Alabama at Birmingham Birmingham Alabama USA

10. Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Aurora Colorado USA

11. Centre of Excellence in Long‐acting Therapeutics (CELT) University of Liverpool UK

Funder

National Institutes of Health

Engineering and Physical Sciences Research Council

European Commission

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2099

Reference38 articles.

1. Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

2. Novel Method To Assess Antiretroviral Target Trough Concentrations UsingIn VitroSusceptibility Data

3. Protein Binding in Antiretroviral Therapies

4. Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151

5. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID‐19;Boras B.;bioRxiv

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032;The Journal of Infectious Diseases;2024-06-05

2. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury;Biomedicine & Pharmacotherapy;2024-05

3. Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia;RSC Medicinal Chemistry;2024

4. Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters;Journal of Antimicrobial Chemotherapy;2023-11-23

5. Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research;Journal of Chromatography B;2023-08